Pneumococcal vaccination: Four issues for Western Europe

Biologicals

Volumn 25, Issue 2, 1997, Pages 215-219

  Fedson, David S ^a  

^a Pasteur Merieux MSD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE;

CONFERENCE PAPER; DRUG USE; HUMAN; LOBAR PNEUMONIA; MORTALITY; PRIORITY JOURNAL; WESTERN EUROPE;

PNEUMOCOCCUS;

EID: 0031170913     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.1997.0087     Document Type: Conference Paper

References (15)

1. 1. Fedson DS, Musher DM. Pneumococcal vaccine. In: Plotkin SA, Mortimer EA Jr, eds, Vaccines, 2nd Edn. Philadelphia: WB Saunders, 1994: 517-5564.
2. 2. Fedson DS. A policy for the prevention of pneumococcal disease. In: Mayon-White R, ed. The clinical impact of pneumococcal disease and strategies for its prevention. International Congress and Symposium Series No 210. Royal Society of Medicine Press, Ltd., 1995: 49-61.
3. 3. Fedson DS, Shapiro ED, LaForce FM et al. Pneumococcal vaccine after 15 years of use: another view. Arch Intern Med 1994; 154: 2531-2535.
4. 4. Hofmann J, Cetron MS, Farley MM et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med 1995; 333: 481-486.
5. 5. Plouffe JF, Breiman RF, Facklam RR, for the Franklin County Pneumonia Study Group. Bacteremia with Streptococcus pneumoniae in adults. Implications for therapy and prevention. J Am Med Assoc 1996; 275: 194-198.
6. 6. Hedlund JA, Svenson SB, Kalin M et al. Incidence, capsular types and antibiotic sensitivity of invasive Streptococcus pneumoniae in Sweden. Clin Infect Dis 1995; 21: 948-953.
7. 7. Gaillat J, Zmirou D, Mallaret MR et al. Essai clinique de vaccin antipneumococcique chez les personnes âgées vivant en institution. Rev Epidemiol Santé Publ 1985; 33: 437-444.
8. 8. Comstock GW. Evaluating vaccination effectiveness and vaccine efficacy by means of case-control studies. Epidemiol Rev 1994; 16: 77-89.
9. 9. Fedson DS. Pneumococcal vaccination in the prevention of community-acquired pneumonia: an optimistic view of cost-effectiveness. Semin Respir Infect 1994; 8: 285-293.
10. 10. Fedson DS, Wajda A, Nicol JP et al. "The old man's friend" (letter). Lancet 1993; 342: 561.
11. 11. Fedson DS. Influenza and pneumococcal vaccination of the elderly: newer vaccines and prospects for clinical benefits at the margin. Prevent Med 1994; 23: 751-755.
12. 12. Tengs TO, Adams ME, Pliskin JS et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Analysis 1995; 15: 369-390.
13. 13. Fedson DS, Hannoun C, Leese J et al. Influenza vaccination in 18 developed countries, 1980-1992. Vaccine 1995; 13: 623-627.
14. 14. Fedson DS, Hirota Y, Shin HK et al. Influenza vaccination in 22 developed countries: an update to 1995 Vaccine (in press).
15. 15. Soares S, Kristinsson KG, Musser JM et al. Evidence for the introduction of a multiresistant clone of serotype 6B Streptococcus pneumoniae from Spain to Iceland in the late 1980s. J Infect Dis 1993; 168: 158-163.